Viatris Dishes On Insulin Aspart Biosimilar As Key Date Passes
Company Won Landmark Interchangeable Insulin Glargine Approval In July
Viatris has provided an update on its biosimilar pipeline, covering assets including insulin glargine, insulin aspart, aflibercept and bevacizumab, as part of its second quarter strategic update.
